Abstract:Objective To investigate the effect of Simvastatin on airway inflammation in obese asthma mice and the mechanism. Methods Sixty C57BL/6J mice were randomly divided into four groups: blank control group (group A), obese asthma group (group B), Dexamethasone treatment group (group C) and Simvastatin treatment group (group D). The mice fed with high-fat diet were sensitized and challenged with ovalbumin (OVA) to establish the model of chronic obese asthma. The mice of the group C were treated with Dexamethasone (0.5 mg/kg) daily, and the mice of the group D were treated with Simvastatin (40 mg/kg) daily in 4 weeks. After last OVA challenge, the survival number of mice and mice reaction during challenge in each group were recorded. After the mice were anesthetized, blood, bronchoaveolar lavage fluid (BALF) and lung tissue were collected and kept respectively. The serum FBG, TC, TG, AST and ALT were measured by biochemical analyzer. The total number of white cells and the proportion of leukocytes, eosinophils, neutrophils and macrophages in the BALF were counted under microscope. The structural changes and inflammation in the lung tissue sections of mice were observed and recorded. Results The airway inflammation score, the total number of white blood cells and neutrophil proportion in the BALF and serum TC levels were higher in the groups B, C and D than those in the group A; the above indexes in the group D significantly decreased compared with the groups B and C (P < 0.05). Serum TC level was positively correlated with the proportion of neutrophils in the BALF (r = 0.724, P = 0.020). Conclusions Simvastatin can alleviate airway inflammation and asthma attack partly by correcting lipid disorder.